Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Viagra knockoff

This article was originally published in The Tan Sheet

Executive Summary

Judgment issued May 11 in Pfizer's lawsuit against "Vaegra" marketer Institute of Sexual Research/David Brady imposes fines totaling $160,000; trademark infringement suit against sham impotence treatment was filed April 20 ("The Tan Sheet" April 27, p. 18). The judgment also prevents ISR, doing business as "American Urological Clinic," from using in any way the Viagra mark "or any colorable imitations thereof, including the VAEGRA name or mark," as well as the drug name sildenafil or "Celldenaphil-pc." Judgment requires Brady to distribute a letter to mailing list retracting previous false "statements, implications or suggestions." Separately, in a case brought by Missouri Attorney General, a Kansas City circuit court orders ISR to refund purchasers of Vaegra. The May 18 order imposes $167,000 in investigative and civil penalties...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088478

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel